Dose-dependency in pleiotropic effects of atorvastatin. - Wikidata - awgldk - TriplyDB

Dose-dependency in pleiotropic effects of atorvastatin.

Dose-dependency in pleiotropic effects of atorvastatin.

http://www.wikidata.org/entity/Q37321653

about

A low-dose atorvastatin and losartan combination directly improves aortic ring relaxation and diminishes ischaemic-reperfusion injury in isolated rat hearts A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats.

P2860

Q36577081-5C66196E-5D24-4B89-84E0-A44201C6AEDA Q41848559-A01AB56A-D4DC-40E9-B43C-D5C01CDDBB8E

P2860

Dose-dependency in pleiotropic effects of atorvastatin.

http://www.wikidata.org/entity/Q37321653

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Dose-dependency in pleiotropic effects of atorvastatin.

@en

Dose-dependency in pleiotropic effects of atorvastatin.

@nl

type

label

Dose-dependency in pleiotropic effects of atorvastatin.

@en

Dose-dependency in pleiotropic effects of atorvastatin.

@nl

prefLabel

Dose-dependency in pleiotropic effects of atorvastatin.

@en

Dose-dependency in pleiotropic effects of atorvastatin.

@nl

P1433

Q37321653-77C8AC05-532B-42B2-9F48-3EF3B7C31E3D

P1476

Q37321653-2BB6126E-9F40-4B8F-8704-9100FEDECEF2

P2093

Q37321653-356F32CD-25AB-4A5F-9396-1D37A30F89BC

Q37321653-86437C02-60FD-44C4-B796-1ED24335DE1D

Q37321653-8D1820DD-906C-408E-A13B-4039B5C4EAE5

Q37321653-D633DBFE-1790-4CFA-86E3-69CDE0F291C9

Q37321653-F7BD01D5-C90F-4FC6-833F-AEAA0DBB23EB

Q37321653-FC4CAE88-8CC0-42AB-820D-0881FB17430E

P2860

Q37321653-06894B25-538A-454A-BB02-1413210E01A3

Q37321653-08902545-8AB5-4C6A-93D0-5739BEFD37C6

Q37321653-0F10D118-1B7C-4CE6-BA0E-90E66C8853EE

Q37321653-1F6F9589-3A00-4838-85F4-11C37C895EC3

Q37321653-3D64A4EA-BA04-4EE3-A902-0F16B35D3E6A

Q37321653-576992CF-3C5E-48BA-A78F-AB6F3438E221

Q37321653-78E24366-EDE2-450A-84FB-A289A700A171

Q37321653-85C44049-CCE5-49C7-92EF-4A44EE02FF6A

Q37321653-8F4F2F88-15A1-457E-B76C-2420FEF9200F

Q37321653-A2B1B5FB-2261-406A-B09F-7523C7DADBCE

P304

Q37321653-0976C7A0-654C-45F8-8F62-E9AB0EA2FE3B

P31

Q37321653-F45B2DFC-3DC9-4D67-94C9-E39DE3A32D0B

P356

Q37321653-DE800281-8965-4B32-8AF4-DCCB130CB0F2

P433

Q37321653-6C1EEB52-FF13-4523-B52D-ACBA292D1F46

P478

Q37321653-73467875-9A00-4C5E-8672-64BF7F85976B

P577

Q37321653-867C9C38-9FE0-4983-8D10-4BB772B3AE57

P5875

Q37321653-9DA1D748-9DA9-4960-86D5-6A73D8C2C5FD

P698

Q37321653-D884032E-8C39-4D36-B606-B924D578CCD8

P932

Q37321653-C74F593E-0CC5-4DFF-8A6D-4AAA57A2D2A2

P356

P1433

The International journal of angiology : official publication of the International College of Angiology, Inc

P1476

Dose-dependency in pleiotropic effects of atorvastatin.

@en

P2093

Akiko Ikai

http://www.w3.org/2001/XMLSchema#string

Kunihisa Miwa

http://www.w3.org/2001/XMLSchema#string

Masaki Ikemoto

http://www.w3.org/2001/XMLSchema#string

Masatoshi Fujita

http://www.w3.org/2001/XMLSchema#string

Mayu Takeda

http://www.w3.org/2001/XMLSchema#string

Tatsuya Morimoto

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

Utility of inflammatory markers in the management of coronary artery disease

Evaluation of methods for the measurement of low-density lipoprotein cholesterol.

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits.

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors.

Isoprenoids as mediators of the biological effects of statins

Determination of 8-hydroxydeoxyguanosine by an immunoaffinity chromatography-monoclonal antibody-based ELISA.

Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease.

P304

89-91

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1055/S-0031-1278256

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223959136

http://www.w3.org/2001/XMLSchema#string

P698

22477299

http://www.w3.org/2001/XMLSchema#string

P932

2733023

http://www.w3.org/2001/XMLSchema#string